M. Dorreen
Impact in
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment
-
- Chronic Lymphocytic Leukemia Research
Papers in ⓘ
-
- Lymphoma Diagnosis and Treatment 8
- Oncology 11
- Neutropenia and Cancer Infections 4
- Cancer Treatment and Pharmacology 2
- Viral-associated cancers and disorders 2
- Co-authors
- Tim Lister (6 shared papers)P. F. M. Wrigley (6 shared papers)A G Stansfeld (4 shared papers)J A Habeshaw (2 shared papers)A. E. Jones (2 shared papers)M. Fox (1 shared paper)Stefan Glück (2 shared papers)Pedro López (2 shared papers)
- Journals
- British Journal of Cancer (3 papers)European Journal of Cancer (2 papers)Clinical Oncology (2 papers)Hematological Oncology (2 papers)Cancer (1 paper)
- Partner nations
- United KingdomCanada
In The Last Decade
M. Dorreen
23 papers receiving 363 citations
Peers
Comparison fields: 5 of 52
- Pathology and Forensic Medicine 178
- Genetics 74
- Oncology 151
- Hematology 43
- Immunology 80
Countries citing papers authored by M. Dorreen
This map shows the geographic impact of M. Dorreen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Dorreen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Dorreen more than expected).
Fields of papers citing papers by M. Dorreen
This network shows the impact of papers produced by M. Dorreen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Dorreen. The network helps show where M. Dorreen may publish in the future.
Co-authors
The 25 scholars most cited alongside M. Dorreen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1984 | 57 | |
| 2 | 1997 | 35 | |
| 3 | 1992 | 35 | |
| 4 | 1983 | 32 | |
| 5 | 1982 | 31 | |
| 6 | 1992 | 27 | |
| 7 | 1984 | 24 | |
| 8 | 2013 | 20 | |
| 9 | 1998 | 19 | |
| 10 | 1984 | 19 | |
| 11 | 1991 | 18 | |
| 12 | 1986 | 13 | |
| 13 | 1988 | 12 | |
| 14 | 1992 | 8 | |
| 15 | 2012 | 8 | |
| 16 | 2014 | 8 | |
| 17 | 1993 | 6 | |
| 18 | 1984 | 6 | |
| 19 | 1988 | 4 | |
| 20 | A 3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer. | 2004 | 4 |
About M. Dorreen
M. Dorreen is a scholar working on Pathology and Forensic Medicine, Oncology, Genetics, Pulmonary and Respiratory Medicine and Rheumatology, having authored 23 papers that have together received 390 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (8 papers), Lung Cancer Treatments and Mutations (4 papers), Neutropenia and Cancer Infections (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Multiple and Secondary Primary Cancers (3 papers), Cancer Treatment and Pharmacology (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Viral-associated cancers and disorders (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (178 citations), Genetics (74 citations), Oncology (151 citations), Hematology (43 citations) and Immunology (80 citations). M. Dorreen has collaborated with scholars based in United Kingdom and Canada. Frequent co-authors include Tim Lister, P. F. M. Wrigley, A G Stansfeld, J A Habeshaw, A. E. Jones, M. Fox, Stefan Glück, Pedro López, T. Younis and Colin Germond. Their work appears in journals such as British Journal of Cancer, European Journal of Cancer, Clinical Oncology, Hematological Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.